

**ALL ORDERS MUST BE SIGNED, DATED AND TIMED BY PHYSICIAN**

**Allergies/Reactions:**

- |  |  |
|--|--|
| <input type="checkbox"/> Puyallup Infusion Center - Fax: 253-697-5066    | <input type="checkbox"/> Gig Harbor Infusion Services - Fax: 253-530-8069  |
| <input type="checkbox"/> Allenmore Infusion Services - Fax: 253-864-4052 | <input type="checkbox"/> DHEC Infusion Center - Fax: 509-755-5845          |
| <input type="checkbox"/> Auburn Infusion Services - Fax: 253-876-8282    | <input type="checkbox"/> North Spokane Infusion Center - Fax: 509-232-2531 |

**ORDERS WITH CHECK BOXES**

When an order is optional (those with check boxes), physicians are responsible for indicating a check mark in the box next to the order. Orders left unchecked will not be initiated.

**Risankizumab (Skyrizi)**

Patient Name: \_\_\_\_\_ Requested Date of Service: \_\_\_\_/\_\_\_\_/\_\_\_\_

Date of Birth: \_\_\_\_/\_\_\_\_/\_\_\_\_ Patient Phone Number: ( \_\_\_\_ ) \_\_\_\_\_ - \_\_\_\_\_  May leave message

**ICD -10 Code:**

- Diagnosis:**
- |  |                                |
|--|--------------------------------|
| <input type="checkbox"/> Crohn's Disease   | <input type="checkbox"/> _____ |
| <input type="checkbox"/> Ulcertive Colitis | <input type="checkbox"/> _____ |

**Required:** H&P with documentation to support above diagnosis including ICD-10 code and supporting labs and documentation.  
**\*\*If required documentation not received with order, scheduling of treatment will be delayed until complete information is available\*\***

**Baseline labs required:**

- CBC, CMP
- Latent TB testing, Date: \_\_\_\_/\_\_\_\_/\_\_\_\_ Results: \_\_\_\_\_
- HBV screening, Date: \_\_\_\_/\_\_\_\_/\_\_\_\_ Results: \_\_\_\_\_
- HCV screening, Date: \_\_\_\_/\_\_\_\_/\_\_\_\_ Results: \_\_\_\_\_
- HIV screening, Date: \_\_\_\_/\_\_\_\_/\_\_\_\_ Results: \_\_\_\_\_

\*Patients should be up to date with all immunizations before initiating therapy. Avoid the use of live vaccines in patients undergoing Risankizumab treatment

**IV Access:** Access and/or maintain IV site in accordance with MHS IV Therapy P&P: Peripheral IV Device Site Selection, Insertion, Maintenance, and Discontinuation; and Maintenance of Central Venous Catheters-Flushing, Dressing Changes and Removal.

**Treatment Regimen for Risankizumab (Skyrizi) dose:**

- Crohn's Disease - 600 mg IV infusion over 1 hour at week 0, 4, and 8.
- Ulcerative Colitis - 1200 g IV over 2 hours at week 0, 4, and 8.

**Maintenance dose for both:** 180 pr 360 mg SUBQ at week 12 then every 8 weeks thereafter.

**\*\*Medicare will not cover SUBQ in outpatient setting**

**Vital Signs:** Check vital signs prior to and at completion of infusion.  
 Contact provider if systolic BP >180; diastolic BP >100; systolic BP<90; HR >110; temp >38C (100.4F)

**If hypersensitivity develops (fever, chills, hypotension, rigors, itching, rash, etc.):**

- Consult MultiCare hypersensitivity guideline for treatment management
- Notify provider of reaction, assessment and need for further orders

**Code Status: Please note, patients will be considered FULL Code unless marked otherwise. If the patient has a POLST, advance directive or living will, please include a copy with the orders.**

Provider Signature \_\_\_\_\_ Print Name \_\_\_\_\_ Date \_\_\_\_\_ Time \_\_\_\_\_

**Order expires in 12 months\*\***

**Patient Identification - Always Attach Patient Label**

Name:  
 MRN #:  
 CSN #:  
 Age / Sex and Gender:

Pre-printed Order  
**CROHN'S DISEASE**

